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Portal hypertensive gastropathy (PHG) results from increased 
resistance to portal blood flow in patients with liver disease 
(with and without cirrhosis) and the consequent elevation 
in portal pressure. Elevated portal pressure induces local 
hemodynamic changes, thus causing congestion in the stomach 
and gastric tissue damage.[1‑3] However, the existence of any 
correlation of the severity of PHG with the degree of portal 
pressure, hyperkinetic state, and hepatocellular dysfunction 
is controversial.[4‑8] There may be other factors involved in its 
physiopathology, including local factors connected with the 
gastric mucosa, alterations in local blood flow, nitric oxide, 
endothelins, or growth factors, as yet unidentified factors.[4]
In cirrhotic patients with portal gastropathy, there is activation 
of cytokines and growth factors, such as interleukin (IL)‑6 
and tumor necrosis factor‑alpha (TNF‑α).[9] TNF‑α 
activates endothelial constitutive nitric oxide synthase and 
endothelin‑1 in the portal hypertensive gastric mucosa.[3] 
Overexpressed nitric oxide synthase produces an excess 
of nitric oxide, which induces hyperdynamic circulation 
and peroxynitrite overproduction. Overexpression of 
peroxynitrite together with endothelin‑1 affects gastric 
mucosal defenses, which are impaired in portal hypertension.
Helicobacter pylori is a major etiological factor of peptic 
ulcer disease (PUD). It is supposed to be a risk factor for 
the more frequently encountered PUD in patients with 
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Background/Aim: We aimed to assess the influence of Helicobacter pylori and its virulent factors, cytotoxin 
associated gene (cag) A and E, on portal hypertensive gastropathy (PHG) and the levels of interleukin 
(IL)‑8, IL‑10, and tumor necrosis factor‑alpha (TNF‑α). Patients and Methods: The patients with cirrhosis 
underwent screening endoscopy and the lesions related to PHG were graded. Biopsies were obtained for 
histology, and polymerase chain reaction (PCR) of H. pylori 16S rRNA, cagA, cagE, and tissue cytokine levels 
was carried out. Absent or mild PHG was compared with moderate to severe PHG. Results: One hundred 
and forty patients with cirrhosis were studied; males numbered 92 and the mean age of the patients was 
50.3 ± 12.0 years, H. pylori positivity in 87 (62.1%) patients was associated with male gender (P = 0.032), 
younger age (P = 0.029), hepatitis D etiology (P = 0.005), higher serum albumin (0.000), lower Child Pugh 
score (P = 0.001), and lower portal vein diameter (P = 0.001). There was no significant difference in the 
levels of TNF-α and IL‑8. However, a decrease in the anti‑inflammatory cytokine IL‑10 was noted with 
moderate to severe gastropathy. Four H. pylori strains were positive for both cagA and cagE, while four 
were positive for cagA only. All the four patients with both virulent factors had mild gastropathy only. 
Conclusion: The presence of H. pylori infection neither affected the severity of PHG nor augmented the 
IL‑8 and TNF‑α levels. There was a decline of virulent H. pylori strains and IL‑10 levels in patients with 
advanced PHG.
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liver cirrhosis.[10] The prevalence of H. pylori in cirrhotics is 
similar to that in controls, and investigators have evaluated 
the effect of H. pylori on liver cirrhosis and PHG and have 
obtained controversial results.[11,12] Colonization of the 
gastric mucosa by H. pylori might have an indirect role in 
PHG as colonization is, at least theoretically, associated 
with inflammation. H. pylori virulence factors induce 
proinflammatory cytokines such as IL‑1, IL‑8, and TNF‑α, 
which influence mucosal inflammation and/or gastric acid 
secretion.[13]
The aim of this study was to find if there is any correlation 
of H. pylori and its virulence factors, cytotoxin‑associated 
gene (cag) A and E, with PHG severity as graded by 
Baveno classification and to assess the expression of 
the proinflammatory cytokines, IL‑8 and TNF‑α, and 
anti‑inflammatory cytokine, IL‑10, in patients with or 
without H. pylori infection.
PATIenTs AnD MeTHODs
Patients
Consecutive patients with cirrhosis, who referred to the 
endoscopy unit of the Aga Khan University Hospital, were 
enrolled. The study was approved by the Ethics Review 
Committee of the hospital. Upper gastrointestinal (GI) 
endoscopy was performed as a part of the assessment of 
portal hypertension. Informed consent was obtained from 
the patients for participation in the study and for gastric 
biopsies from the antrum. Diagnosis of cirrhosis was based 
on clinical, biochemical, and radiological findings or on liver 
biopsy that was done previously. The severity of cirrhosis was 
assessed using the Child Pugh classification.[14] The etiology 
of the cirrhosis was defined as viral when hepatitis B surface 
antigen (HBsAg) or antibodies to hepatitis C virus (HCV) 
were present or alcoholic if there was a daily ethanol intake 
of >60 g/day for at least 5 years. Diagnosis of other less 
common diseases, such as non‑alcoholic fatty liver disease, 
autoimmune liver disease, and primary biliary cirrhosis, was 
based on the latest diagnostic criteria.
Inclusion and exclusion criteria
The inclusion criteria for selection of the study population 
included patients undergoing screening endoscopy for varices, 
with or without history of previous upper GI bleeding. The 
exclusion criteria included the following: History of previous 
band ligation or sclerotherapy for esophageal varices; patients 
on beta blockers, nitrates, nonsteroidal anti‑inflammatory 
drugs, aspirin, proton pump inhibitors, or histamine 2 receptor 
antagonists; pregnant and lactating females; patients with 
inflammatory bowel disease, celiac disease, or other systemic 
diseases affecting the GI tract; patients on antibiotics within 
last 2 weeks; patients with any ongoing infection; patients with 
ongoing ingestion of alcohol; patients with gastric neoplasia; 
patients who had undergone surgery for the correction of portal 
hypertension, gastrectomies, and/or vagotomies; patients with 
thrombosis of the portal or suprahepatic veins or inferior vena 
cava; patients not willing to participate; and patients with 
prothrombin time greater than 20 s.
endoscopic examination
All patients had upper GI endoscopy (GIF 180, Olympus 
Tokyo, Japan) performed by a single experienced endoscopist to 
prevent interobserver variability. Sterilized biopsy forceps were 
used to obtain gastric biopsy specimens from the antrum. Two 
biopsy specimens were removed for histology and dispatched 
in a formalin‑containing container. Gastric biopsy specimens 
obtained for RNA extraction were collected in an eppendorf 
containing TRIzol Reagent (Invitrogen Corporation, Carlsbad, 
California, USA) and stored in a liquid nitrogen container for 
transport to the laboratory and stored at −70°C for further 
use. The proforma section related to the endoscopic findings 
was filled by the assistant during the procedure.
Grading of portal hypertensive gastropathy
Baveno classification was used to classify portal 
gastropathy.[15,16] Mosaic pattern was defined as small 
polygonal areas demarcated by a distinct white to yellow 
border and with or without a slight central bulge, which 
had a mosaic, fish scale‑like appearance upon endoscopy. 
The lesions were graded as were graded as mild (if the color 
of the mucosa was pink) and severe when diffuse erythema 
(redness) of the mucosa was present [Table 1]. Red markings 
defined as flat or slightly bulging red lesions were seen in 
the gastric mucosa. Such lesions included fine punctate 
hemorrhagic spots and discrete cherry red spots. The lesions 
were graded as (1) isolated discrete spots and cherry red spots 
and (2) when confluent areas of submucosal hemorrhage. 
Presence of flat or slightly raised red stripe‑like lesions 
radiating from the pylorus to the antrum and the body of 
the stomach for a variable distance was described as gastric 
antral vascular ectasia (GAVE). Black and brown spots due 
to old submucosal hemorrhage were not scored. Presence of 
oozing of blood from gastropathy was also noted. Patients of 
table 1: Baveno scoring system for endoscopic 
appearance in portal hypertensive gastropathy
Mucosal mosaic pattern
Mild 1
Severe 2 
Red markings
Isolated 1
Confluent 2
Gastric antral vascular ectasia
Absent 0
Present 2
6 (Maximum score)
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absent to mild gastropathy (score 0‑2) were compared with 
those of moderate to severe gastropathy (score 3‑6).
Documentation of varices
Esophageal varices were classified as small or large, where 
small esophageal varices were defined as varices that 
flattened with insufflations or minimally protruded into 
the esophageal lumen, while large esophageal varices were 
defined as varices that protruded into the esophageal lumen 
and touched each other (presence of confluence) or that 
filled at least 50% of the esophageal lumen. Gastric varices 
were documented according to the location, as described 
by Sarin et al.[17]
Assessment of portal hypertension and liver 
dysfunction
Noninvasive methods like portal vein diameter, splenic size 
on ultrasound, platelet count, and aspartate aminotransferase 
to platelet ratio index (APRI) and platelet spleen diameter 
ratio were used to assess portal hypertension. Severity of liver 
dysfunction was judged by Child Pugh score and Model for 
End‑stage Liver Disease (MELD) score.
Diagnosis of H. pylori infection
Diagnosis of H. pylori infection was based on histopathology 
of gastric biopsy and polymerase chain reaction (PCR) for 
H. pylori 16S rDNA.[18]
Histology
Gastric biopsy specimens were fixed immediately in 10% 
formalin in sodium phosphate buffer (4 g/L monobasic and 
6.5 g/L dibasic; Fisher, Morris Plains, NJ, USA) and sent to 
the Department of Pathology for processing. Biopsies were 
embedded in paraffin, and histological sections were stained 
with hematoxylin and eosin, and Giemsa for evaluation.
extraction of DnA from tissue
DNA extraction from gastric biopsy tissue was carried out as 
described before.[18] Briefly, gastric tissue was homogenized 
to uniformity in 500 μl of sterile water and centrifuged 
at 12,000 × g for 3 min. Five hundred microliters of lysis 
buffer [100 mM NaCl, 10 mM Tris‑HCl (pH 8.0), 25 mM 
ethylenediaminetetraacetic acid (EDTA), 0.5% sodium 
dodecyl sulfate] and 10 μl of proteinase K (10 mg/ml) were 
added. Incubation was carried out at 56°C for 20 hours; this 
was followed by phenol‑chloroform extraction and ethanol 
precipitation. The resulting pellet was allowed to dissolve in 
40 μl of TE buffer [10 mM Tris‑HCl (pH 7.4) and 0.1 mM 
EDTA (pH 8.0)] for 20 hours at 37°C. Samples were stored 
at −20°C before PCR amplification was performed. DNA 
content and purity was determined by measuring the 
absorbance at 260 nm and 280 nm, respectively, using a 
spectrophotometer (Beckman DU‑600, Brea, California, USA).
PcR for H. pylori 16s rDnA, cagA, and cagE
PCR was performed using extracted DNA as the template. 
Helicobacter genus specific 16S rRNA, cagA, and cagE primers[19] 
[Table 2] were used to amplify the respective gene products.[18,19] PCR 
amplification was carried out in a total volume of 50 μl containing 
2 μl of 2 mM deoxyribonucleotide triphosphates (dNTPs), 1 μl 
containing 50 pmol of primer 1, 1 μl containing 50 pmol of primer 
2 (synthesized by Applied Biosystems, Inc, Foster automatic 
synthesizer California, USA), 1 unit of Taq DNA polymerase 
(Promega Corporation, Madison, Wisconsin,USA), 5 μl of 10× 
PCR reaction buffer, 3 mM of MgCl2, and 2 μl of DNA template 
containing 0.5 ng of extracted DNA, and the total volume was 
rounded to 50 μl with double distilled water. The reaction was 
carried out in a Perkin Elmer 9700 thermal cycler. The amplification 
cycle consisted of an initial denaturation of target DNA at 94°C 
for 5 min and then denaturation at 94°C for 1 min, primer 
annealing at 56°C for 1 min, and extension at 72°C for 1 min. 
The final cycle included an extension step at 72°C for 5 min to 
ensure full extension of the product. Samples were amplified 
through 35 consecutive cycles. Negative reagent control reactions 
were performed with each batch of amplifications, consisting of 
tubes containing distilled water in place of the DNA samples. Five 
microliters of PCR product was electrophoresed on a 2% agarose 
gel to ensure homogeneity and yield. PCR amplification resulted 
in a homogeneous DNA fragment of the expected size of 400 bp 
for 16S rDNA of H. pylori.
Tissue cytokines using real‑time quantitative 
polymerase chain reaction with sBG
Total RNA was extracted from the endoscopic biopsy 
samples of gastric mucosa with TRIzol method described 
table 2: Primer sequence
Gene sequence Primer 
design 
5’→3’
Helicobacter 
16S rRNA[24]
C97 GCT ATG ACG GGT ATC C F
C98 GAT TTT ACC CCT ACA CCA R
cagA[15]
GGTCAAAATGCGGTCATGG F
TTAGAATAATCAACAAACATCACGCCAT R
cagE[15] 5’-GCGATTGTTATTGTGCTTGTAG-3’ F
5’-GAAGTGGTTAAAAAATCAATGCCCC-3’ R
IL‑10[16] 5′‑ ACGGCGCTGTCATCGATT‑3’ F
5’ GGCATTCTTCACCTGCTCCA-3’ R
IL‑8[16] 5′‑ACTGCGCCAACACAGAAATT‑3′ F
5′‑TTCTCCACAACCCTCTGCAC‑3′ R
TNF‑α[16] 5′‑CCCTGGTATGAGCCCATCTATC‑3′ F
5′‑AAAGTAGACCTGCCCAGACTCG‑3′ R
GAPDH[16] 5′‑GAAGGTGAAGGTCGGAGTC‑3′ F
5′‑GAAGATGGTGATGGGATTTC‑3′ R
F: Forward primer, R: Reverse primer
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previously.[20] Reverse transcription of the extracted RNA 
was performed using RNase H–deficient reverse transcriptase 
(Superscript II; Life Technologies New York, USA) and 
oligo (dT) primers (Life Technologies). Aliquots (2 μl) of 
reverse transcription reaction mixture (20 μl) were used 
for quantification of IL‑8, IL‑10, TNF‑α, and GAPDH 
Glyceraldehyde‑3‑Phosphate Dehydrogenase (GAPGH) gene 
expression by real‑time PCR assays [Table 2]. The SYBR 
Green based quantitative real time polymerase chain reaction 
(SABG QRT‑ PCR) was used to quantify IL‑8, IL‑10, TNF‑α, 
and GAPDH gene expression (PE Applied Biosystems, Foster 
City, CA, USA). The PCR reactions were performed using 
the SYBR Green (SBG) PCR kit (PE Applied Biosystems). 
After activation for 10 min at 95°C, 40 cycles of 15 s at 95°C 
and 1 min at 62°C were carried out in model icycler (Biorad 
Hercules, CA, USA). Real‑time fluorescence measurements 
were recorded and the threshold cycle (Ct) value for each 
sample was calculated by the above sequence detector. For 
TNF‑α and GAPDH, standard curves of Ct values were 
obtained from real‑time PCR of pMFGhTNF and PCRII 
GAPDH (reference plasmids). Ct values for IL‑8, IL‑10, 
TNF‑α, and GAPDH transcripts from clinical specimens 
were plotted on the standard curves, and the amounts (in 
picograms) of each transcript were calculated. The amounts 
of IL‑8, IL‑10, and TNF‑α transcripts (pg) were expressed 
relative to that of GAPDH (pg). Each biopsy sample obtained 
from the same patient was tested in duplicate, and the average 
of two Ct values was used in this study.
statistical analysis
The sample size was calculated by A‑priori sample size 
calculator for studies using two‑tailed Student’s t values for 
comparison (http://www.danielsoper.com/statcalc). A sample 
of 128 analyzable subjects provides an 80% power at the 
0.05 alpha level. So, the initial plan was to include 64 H. pylori 
positive and 64 negative patients. The Statistical Package for 
Social Science (SPSS, Release 19) was used for data analysis 
and Prism GraphPad (version 5) for graphics. The descriptive 
analysis was done for demographic and clinical features. Results 
were presented as a mean ± standard deviation for quantitative 
variables and number (percentage) for qualitative variables. 
Independent sample Student’s t‑test was used for continuous 
variables. Homogeneity of variances was assessed by Levene 
test and the corrected P value was used. Chi‑squared test or 
Fisher’s exact test was used for categorical variables. Factors 
found to be statistically significant in univariate analysis were 
included in a multivariate regression analysis. All P values were 
two sided and the significance level was defined as P < 0.05.
ResULTs
One hundred and forty patients with cirrhosis were studied, 
with males numbering 92, and the mean age of the patients 
was 50.3 ± 12.0 years. PHG was graded as negative in 
16 (11.4%), mild in 48 (34.3%), moderate in 44 (31.4%), 
and severe in 32 (22.9%) patients. H. pylori was present 
in 87 (62.1%) of the patients. The presence of H. pylori 
was associated with male gender (P = 0.032), younger 
age (P = 0.029), hepatitis D etiology (P = 0.005), 
higher serum albumin (P = 0.000), lower Child Pugh 
score (P = 0.001), and lower portal vein diameter 
table 3: comparison of Helicobacter pylori positive 
and negative patients with cirrhosis of liver
H. pylori 
present 
(n=87)
H. pylori 
absent 
(n=53)
P value
Gender
Male 63 29 0.032
Female 24 24
Age, years (mean±SD) 48.6±12.6 53.1±11.0 0.029
Etiology
Hepatitis C 50 38 0.018
Hepatitis B 16 13
Hepatitis B+D 18 02
Non-B Non-C 03 00
Child class
A 73 31 0.002
B 14 20
C 0 2
Child Pugh score 5.6±1.0 6.4±1.5 0.001
MELD score 8.4±5.2 10.4±7.2 0.069
Portal vein diameter 10.2±2.2 11.6±2.4 0.001
Spleen size 14.1±3.5 13.6±2.3 0.392
APRI score 1.64±1.8 1.45±1.1 0.499
Platelet to spleen ratio 1000±512 913±441 0.216
Esophageal varices
Absent 33 13 0.223
Small 16 14
Large 38 26
Esophageal varices red signs 16 20 0.011
Gastric varices 8 2 0.227
Mosaic pattern
Present 56 38 0.371
Absent 31 15
Red markings
Present 30 10 0.035
Absent 57 43
Portal gastropathy
Absent 11 5 0.526
Mild 26 22
Moderate 28 16
Severe 22 10
IL-8 1.73±2.6 2.54±3.1 0.718
IL-10 0.99±1.66 0.97±1.69 0.955
TNF‑α 4.70±3.1 5.09±6.4 0.094
MELD: Model for end-stage liver disease, APRI: Aspartate aminotransferase 
to platelet ratio index, TNFα: Tumor necrosis factor alpha, IL: Lnterleukin, 
SD: Standard deviation
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thinning of the vascular wall, and increased area of the 
gastric mucosa occupied by vessels.[21] It apparently results 
from elevated portal pressure which induces changes of 
local hemodynamics, thus causing congestion in the upper 
stomach and gastric tissue damage.
The relationship of the functional status of liver and 
the development of PHG is not straightforward and is 
controversial.[4‑8] Altered vascular hemodynamics occurring 
in PHG may not be purely a local phenomenon of the 
stomach and may be a part of a generalized vascular 
abnormality of cirrhosis and portal hypertension.[6] The 
results of a study suggested that there were no statistically 
significant differences in the level of hepatic venous 
pressure gradient (HVPG) between patients with PHG 
and those without PHG and between patients with mild 
PHG and those with severe PHG.[4] Moreover, Child Pugh’s 
classification, systemic vascular resistance index, and 
glucagon levels were also not different among the different 
grades of PHG.[4] Another study had a similar conclusion,[8] 
while a study conducted by Kim et al. concluded that 
PHG was associated with portal hypertension severity and 
prognosis in patients with cirrhosis.[5] In our study, the 
severity of PHG correlated with the variables known to 
reflect portal hypertension. However, we did not measure 
HVPG. We could not find any correlation of Child Pugh 
and MELD scores, which measure liver dysfunction, with 
the severity of PHG.
(P = 0.001). There were no significant differences in the 
levels of TNF‑α, IL‑8, and IL‑10 in biopsies with or without 
H. pylori [Table 3 and Figure 1].
Moderate to severe gastropathy (n = 76) was associated 
more with male gender (P  = 0.030), hepatitis B 
etiology (P = 0.020), larger spleen diameter (P = 0.000), 
greater APRI score (P = 0.021), lesser platelet to spleen 
ratio (P = 0.000), and presence of varices (P = 0.000) 
and gastric varices (P = 0.002). No effects of age, Child 
Pugh score, MELD score, and presence of H. pylori on the 
severity of PHG could be found. There was no significant 
difference in the levels of TNF‑α and IL‑8. However, a 
decrease in the anti‑inflammatory cytokine IL‑10 was noted 
with moderate to severe gastropathy [Table 4 and Figure 2]. 
Regression analysis showed that male gender and presence of 
esophageal and gastric varices were independently associated 
with moderate to severe PHG (P = 0.046, 0.05, and 0.042 
respectively).
Four H. pylori strains were positive for both cagA and cagE, 
while four were positive for cagA only. All the four patients 
with both virulent factors had mild gastropathy only.
DIscUssIOn
PHG can lead to chronic blood loss and transfusion‑dependent 
anemia, as well as acute bleeding episodes. It is associated 
with dilation and tortuosity of the submucosal vessels, 
Figure 1: Interleukin 8, interleukin 10, and tumor necrosis factor alpha levels in Helicobacter pylori positive ad negative patients
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Figure 2: Interleukin 8, interleukin 10, and tumor necrosis factor alpha levels in absent to mild versus moderate to severe gastropathy
H. pylori is considered a risk factor for PUD in cirrhotic 
patients.[22] There is a significant increase in the inducible 
nitric oxide synthase (iNOS) production in patients with 
PHG. H. pylori also increases iNOS expression. However, 
there is no evidence of synergistic action between H. pylori 
and PHG on iNOS expression.[23] Patients with chronic liver 
disease showed higher risk of developing gastroduodenal 
lesions regardless of the presence of the H. pylori infection. 
Many studies failed to find a correlation between the 
severity of PHG and H. pylori infection.[24‑26] During 
advanced gastropathy, the environment for the colonization 
of H. pylori becomes unfavorable, resulting in a decrease 
in the number of patients harboring this organism. In our 
study, the patients harboring H. pylori were of younger 
age, had higher serum albumin, lower Child Pugh score, 
and lower portal vein diameter. So, H. pylori associated 
changes in the mucosa are unlikely to contribute to the 
severity of PHG.
Previous studies have not addressed the issue of virulence 
factors and the role of cytokines in the presence or absence 
of H. pylori in the endoscopic severity of gastropathy. We 
found lower levels of IL‑10 in the mucosa of patients with 
advanced PHG. IL‑10 is an anti‑inflammatory cytokine. 
We propose that IL‑10 might have some protective role 
against the development of severe gastropathy, and as the 
levels decrease, gastropathy becomes severe. As discussed 
earlier, TNF‑α may have a role in the pathogenesis of portal 
gastropathy. We did not compare its levels with those of 
non‑cirrhotic controls. So, it is not possible to exactly find 
how much TNF‑α level is higher in patients with PHG 
compared to non‑cirrhotic controls. However, we could not 
find any significant difference in the levels of TNF‑α and 
IL‑8 in patients with none to mild versus moderate to severe 
gastropathy. Moreover, the H. pylori status did not influence 
the level of these cytokines. Another interesting finding was 
a decline in the H. pylori harboring virulent factors cagA and 
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cagE in patients with moderate to severe gastropathy, which 
reflects a hostile microenvironment for H. pylori in patients 
with advanced PHG and no role of these virulence factors.
In summary, in our study, the severity of PHG did not 
correlate with the severity of liver disease as judged by Child 
Pugh and MELD scoring. The patients with moderate to 
severe PHG had larger spleen, larger esophageal varices, 
and gastric varices. The level of anti‑inflammatory cytokine 
IL‑10 was lower in advanced PHG, but the levels of 
proinflammatory cytokines TNF‑α and IL‑8 were not higher. 
The presence of H. pylori infection did not affect the severity 
of PHG and the levels of IL‑8, IL‑10, and TNF‑α. H. pylori 
with virulent factors (e.g., cagA) was not associated with 
advanced PHG.
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